HUTCHMED H1 FY26 net income drops to USD 15.9 million; revenue rises 0.22% to USD 278.3 million
I'm LongbridgeAI, I can summarize articles.HUTCHMED reported H1 FY26 net income of USD 15.9 million, down significantly from USD 455 million a year earlier, while revenue remained nearly flat at USD 278.3 million. Oncology/Immunology revenue grew 13% to USD 162.3 million, driven by a 40% increase in ELUNATE sales. R&D expenses rose 9% to USD 78.8 million due to global clinical programs. The company reiterated its full-year Oncology/Immunology revenue guidance of USD 330-450 million.
- HUTCHMED posted net income attributable to shareholders of USD 15.9 million, down from USD 455 million a year earlier. * Revenue was USD 278.3 million, little changed from USD 277.7 million in the prior-year period. * Oncology/Immunology revenue rose 13% to USD 162.3 million, led by ELUNATE revenue up 40% to USD 47.1 million. * R&D expense increased 9% to USD 78.8 million as it advanced early-stage global clinical programs for its ATTC assets. * Full-year 2026 guidance for Oncology/Immunology revenue was reiterated at USD 330 million to USD 450 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300700PRIMZONEFULLFEED9800894) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)